Anti-Human CD22 Recombinant Antibody (RFB-4), PerCP (HB011347)

Name: Anti-Human CD22 Recombinant Antibody (RFB-4), PerCP
Brand: abinScience
SKU: HB011347
Price: 268 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50T
100T

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB011347
Species reactivity	Human
Applications	ELISA, FCM
Host species	Mouse
Isotype	IgG1, kappa
Clone ID	RFB-4
Conjugation	PerCP
Clonality	Monoclonal
Target	Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22, RFB4, RFB 4
Endotoxin level	Please contact with the lab for this information.
Associated products	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), PerCP
Accession	P20273
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Background	B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
References	1. Kreitman RJ, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999 Mar 31;81(1):148-55. [HB011347] 2. Mansfield E, et al. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90(5):2020-2026. [HB011347]
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.